Showing results (101-110 of 6,269) with videos related to

Sort By:
Pageof 627
Diabetes, Obesity & Metabolism|October 6, 2015
Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trialM Davies, T Sasaki, J L Gross, et al.
Diabetes, Obesity & Metabolism|November 6, 2015
Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysisU Rohde, N Hedbäck, L L Gluud, et al.
Diabetes, Obesity & Metabolism|May 9, 2012
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)Y Seino, K W Min, E Niemoeller, et al.
Diabetes, Obesity & Metabolism|May 19, 2016
Add-on treatment with intermediate-acting insulin versus sliding-scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy: a randomized crossover studyM C Gerards, J S de Maar, T G Steenbruggen, et al.
Diabetes, Obesity & Metabolism|April 10, 2016
Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitusD J Kazierad, A Bergman, B Tan, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetesCarol Wysham, Bruno Guerci, David D'Alessio, et al.
Diabetes, Obesity & Metabolism|July 14, 2016
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)L-N Ji, C-Y Pan, J-M Lu, et al.
Diabetes, Obesity & Metabolism|July 22, 2017
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitusChristophe Schmitt, Agnès Portron, Shirin Jadidi, et al.
Diabetes, Obesity & Metabolism|July 22, 2017
Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes AuditAdrian H Heald, Mark Livingston, Nagaraj Malipatil, et al.
Diabetes, Obesity & Metabolism|July 26, 2017
Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trialWenying Yang, Kyungwan Min, Zhiguang Zhou, et al.
Pageof 627